Gene therapy of thyroid carcinoma

Normally, differentiated thyroid carcinoma(DTC) is a disease of good prognosis, but about 30% of the tumors are dedifferentiate, which are inaccessible to standard therapeutic procedures such as "operation ¹³¹I therapy mid thyroid hormone". Both internal and abroad experts are researching a new therapy of dedifferentiated thyroid carcinoma——gene therapy. Many of them utilize methods of it, but follow different strategies:(1) transduction of the thyroid sodium/iodide transporter gene to make tissues that do not accumulate iodide treatable by ¹³¹I therapy;(2) strengthening of the anti-tumor immune response;(3) suicide gene therapy;(4) depression the generation of tumor cells;(5) gene therapy of anti-vascularization.